GCP
RLMD icon

GSA Capital Partners’s Relmada Therapeutics RLMD Stock Holding History

GSA Capital Partners’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$979K Buy
141,443
+121,877
+623% +$852K 0.06% 510
2026
Q1 		$136K Buy
+19,566
New +$92.6K 0.01% 1527
2025
Q1 		– Sell
-124,773
Closed -$65K – 2010
2024
Q4 		$65K Buy
124,773
+16,361
+15% +$39.9K ﹤0.01% 1524
2024
Q3 		$351K Buy
108,412
+297
+0.3% +$962 0.03% 1144
2024
Q2 		$324K Buy
108,115
+4,794
+5% +$17.3K 0.02% 1229
2024
Q1 		$480K Sell
103,321
-81,252
-44% -$392K 0.04% 908
2023
Q4 		$764K Sell
184,573
-10,842
-6% -$32.1K 0.06% 545
2023
Q3 		$586K Sell
195,415
-76,109
-28% -$226K 0.05% 697
2023
Q2 		$668K Buy
271,524
+208,926
+334% +$578K 0.07% 556
2023
Q1 		$141K Sell
62,598
-59,992
-49% -$207K 0.01% 1315
2022
Q4 		$428K Buy
+122,590
New +$1.08M 0.05% 698
2022
Q1 		– Sell
-17,429
Closed -$393K – 1773
2021
Q4 		$393K Buy
+17,429
New +$388K 0.05% 753

Other funds holding RLMD

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GSA Capital Partners's RLMD Position: Q2 2026 in Review

GSA Capital Partners increased its Relmada Therapeutics (RLMD) stake by 623% in Q2 2026, buying an estimated $852K and bringing the position to 141,443 shares worth $979K. The position accounts for 0.06% of the portfolio, ranked #510.

GSA Capital Partners first reported a position in RLMD in Q4 2021 and has held it in 12 quarters since. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • GSA Capital Partners held 141,443 shares of Relmada Therapeutics worth $979K as of Q2 2026.
  • GSA Capital Partners bought 121,877 Relmada Therapeutics shares in Q2 2026, an estimated $852K.
  • Relmada Therapeutics made up 0.06% of GSA Capital Partners's portfolio in Q2 2026, its #510 holding.
  • GSA Capital Partners first reported a position in Relmada Therapeutics in Q4 2021 and has held it in 12 quarters since.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.